Latest information on COVID-19
Support teaching, research, and patient care.
Ruth Lathi, MD graduated Massachusetts Institute of Technology with a B.S. in Molecular Biology; she earned her M.D. degree at University of California, San Francisco, and completed her residency training in obstetrics and gynecology at Baylor College of Medicine. She completed her sub-specialty fellowship training in reproductive endocrinology and infertility (REI) at Stanford University.Dr. Lathi joined the faculty at Stanford University in 2003 and is currently a Professor in the Department of Obstetrics and Gynecology, Director of the Multi-specialty Recurrent Pregnancy Loss program at Stanford, and is the Program Director of the REI Fellowship. Dr. Lathi has a special interest in treating recurrent pregnancy loss, the role of preimplantation genetic diagnosis in the treatment of reproductive disorders, and the prognostic value and utility of genetic testing of miscarriage tissues, and long-term outcomes of fertility treatments.Dr. Lathi enjoys mentoring medical students, residents and fellows, and spending time with her family and outdoor activities like golfing, swimming and hiking.
Recurrent miscarriage is left unexplained by standard testing. This study is examining novel sperm quality tests and how the impact risk of pregnancy loss. Participants will be asked to give a sperm sample on 2 separate occasion and receive a copy of their test results at the completion of the study. Couples who have unexplained repeat pregnancy loss are eligible to participate if the female age is < 40 and the male age is 45. Please contact email@example.com for more information.
1195 W. Fremont Avenue, Suite 1301 Sunnyvale, CA 94087
Dr. Lathi’s longstanding interest in miscarriage and recurrent pregnancy loss has led to multiple completed studies on the contribution of embryonic chromosome errors on miscarriage and recurrent miscarriage patients. She has published extensively, on ways to optimize testing of miscarriage and the impact of environmental factors such as age, obesity and endocrine disrupting chemicals on the chromosome make up of miscarriages. Her current research in the field for recurrent pregnancy loss focusses on endometrial contributions to miscarriage, such as progesterone resistance and inflammation, as well as, the contribution of sperm quality to miscarriage. The use of preimplantation genetic testing in the setting of infertility and recurrent miscarriage is controversial, her research explores the risks, benefits, costs and limitations of this treatment. Embryo mosaicism (the combination of normal and abnormal cells within an embryo) leads to inaccuracies in preimplantation genetic testing. Dr. Lathi is currently performing an observational trial to better understand the implantation potential of mosaic embryos. Dr. Lathi recently received NIH funding to study pregnancy outcomes after frozen embryo transfers. Some studies have linked frozen embryo transfer to pre-eclampsia, fetal macrosomia and other placental disorders. Dr. Lathi will be recruiting for a multi-site trial to observe differences in maternal and fetal outcomes based on which fertility medications were used prior to implantation and in the first trimester.
Pregnancy and Developmental Outcomes After Transfer of Reportedly Aneuploid or Mosaic Embryos
To determine how often embryos reported to be abnormal by preimplantation genetic testing
result in liveborn infants. To evaluate whether the pregnancies that result from these
embryos are higher risk for complications and whether the resulting babies have higher risk
for health or developmental issues in the first five years after birth.
View full details
Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility
The purpose of this study is to determine if patients with recurrent pregnancy loss or
unexplained infertility have an altered uterine gene expression or uterine microbiome
(micro-organism composition) during the window of embryo implantation. Furthermore we would
like to assess for women with an abnormal uterine gene expression whether vaginal
progesterone medication improves or alters gene expression and for women with an abnormal
microbiome whether antibiotic treatment followed by probiotic treatment normalizes the
Stanford is currently not accepting patients for this trial.
For more information, please contact Sara J Churchill, MD, 617-513-4997.
Natural Versus Programmed Frozen Embryo Transfer (NatPro)
NatPro is a two-arm, parallel-group, multi-center, randomized trial in which women undergoing
frozen embryo transfer (FET) will be randomized to receive either a modified natural cycle
(corpus luteum present) or a programmed cycle (corpus luteum absent).
Predicting Endometrial Receptivity for Optimal Reproductive Management
The purpose of this study is to understand why some women are infertile (unable to conceive a
child). The investigators hope to learn if an endometrial biopsy after egg retrieval is
feasible for detecting biomarkers for endometriosis and predicting implantation and pregnancy
rate after embryo transfer.
This study design will provide for the first time, an opportunity to compare endometrial
biopsy material from hyperstimulated (gonadotropin treated) subjects after egg retrieval. If
successful, it would provide a new protocol for women with unexplained infertility or those
with known endometriosis to avoid poor IVF outcomes.
Platelet Rich Plasma for Patients With Recurrent Implantation Failure
Patients with recurrent implantation failure are among the most difficult patients to treat,
with no proven standard treatment. Platelet rich plasma stimulates cellular processes
involved in endometrial regeneration, and in a small case series has shown efficacy for this
patient population. We hope to conduct a randomized controlled pilot study to determine
whether PRP is indeed an effective treatment for recurrent implantation failure.
Preimplantation Genetic Testing in Women of Advanced Maternal Age
The GETSET trial is a prospective randomized trial designed to evaluate the clinical outcomes
of incorporating preimplantation genetic testing for aneuploidies (PGT-A) in elective single
embryo transfer in women between 35 and 40 years of age.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth B Lathi, MD, 6504987911.